NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-AT-24-025 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-25-029 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) seeks applications for a single Coordinating Center to support research on the identification and dissemination of signals of emerging drug use patterns in communities across the United States. The Coordinating Center will provide operational, administrative, and logistical support by executing the following: (1) Establish a Scientific Advisory Group to provide guidance and direction. (2) Engage an Early Warning Network composed of two components: local health experts on drug use from selected communities (Sentinel Sites) and a broader network of community-based health researchers, to support the bi-directional sharing of information and insights into drug use patterns in their communities and to support the ongoing monitoring, interpretation, and dissemination of data. (3) Identify, compile, analyze, and triangulate research data and resources from multiple sources to assess and contextualize emerging drug threats. (4) Disseminate contextualized research findings, data, and resources to key audiences who can use the data to inform their response.
Funding Opportunity RFA-DA-25-027 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN) and contribute to the network's capacity to respond to urgent public health needs. NIDA intends to continue to develop and test interventions for addressing the wide spectrum of substance use problems via collaborative partnerships among NIDA, clinical research investigators, community representatives, healthcare providers, and healthcare institutions.
Notice NOT-NR-24-002 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-001 from the NIH Guide for Grants and Contracts
Notice NOT-TR-24-002 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-054 from the NIH Guide for Grants and Contracts. The purpose of the High Impact Specialized Innovation Programs (SIPs) is to support the development and demonstration of unique hub capabilities, research platforms and/or resources to address in a timely manner critical gap areas and/or roadblocks in clinical and translational science at awarded UM1 Clinical and Translational Science Awards (CTSA) Program Hubs (PAR-21-293). Successful programs supported through this funding opportunity are expected to lay a strong foundation for future adoption and/or dissemination of capabilities to additional CTSA Program Hubs.
Funding Opportunity RFA-HG-23-048 from the NIH Guide for Grants and Contracts. This NOFO solicits applications that stimulate innovation and advance understanding of when, where and how best to implement the use and sharing of genomic information and technologies in clinical care in all persons irrespective of racial/ethnic background or socioeconomic status. The R03 grant mechanism supports small research projects that can be carried out in a short period of time with limited resources, such as pilot or feasibility studies; secondary analysis of existing data; small, self-contained research projects; or development of research methodology. An R03 grant application need not have extensive background material or preliminary information. Accordingly, reviewers will emphasize the conceptual framework, the level of innovation, and the potential to significantly advance our knowledge or understanding. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or, when available, from investigator-generated data. Preliminary data are not required for R03 applications; however, they may be included if available.
Notice NOT-AR-23-021 from the NIH Guide for Grants and Contracts
Notice NOT-HD-23-034 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-003 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-194 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-035 from the NIH Guide for Grants and Contracts. Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
Funding Opportunity RFA-HG-23-033 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute intends to issue a Funding Opportunity Announcement (FOA) to solicit applications that stimulate innovation and advance understanding of when, where and how best to implement the use and sharing of genomic information and technologies in clinical care in all persons including populations or communities that experience health disparities, such as racial or ethnic minority groups, people with lower socioeconomic (SES) status, underserved rural communities, and sexual and gender minority groups. The intended FOA will be based on a concept recently approved by the National Advisory Council on Human Genome Research and accompanying discussion. This Notice is being provided to allow potential applicants sufficient time to responsive projects. Details of the planned FOA are provided below.
Funding Opportunity PAR-24-053 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to support projects to test prospective multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. These research projects will be part of the Multi-Sectoral Preventive Interventions (MSPI) Research Network, which will also include a Coordinating Center (NOFO xxx). Funded under a cooperative agreement, projects participating in the MSPI Research Network will collaborate to share approaches, methods, and data, working closely with NIH Institutes, Offices and Centers. Applicants applying to this NOFO are encouraged to review the Coordinating Center NOFO to fully understand the MSPI Research Network structure and activities. This NOFO solicits bi-phasic research projects proposed in UG3/UH3 Phased Innovation Awards Cooperative Agreement applications. Funding for the UG3 phase (phase I) will be used to demonstrate sufficient preparation, feasibility and capacity to meet foundational milestone targets specific to the work proposed. A UG3 project that meets its milestones will be administratively considered by NIH and prioritized for transition to the UH3 award (phase II). Applicants responding to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases.
Funding Opportunity PAR-24-036 from the NIH Guide for Grants and Contracts. Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-HG-23-032 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute intends to issue a Funding Opportunity Announcement (FOA) to solicit applications that stimulate innovation and advance understanding of when, where and how best to implement the use and sharing of genomic information and technologies in clinical care in all persons including populations or communities that experience health disparities, such as racial or ethnic minority groups, people with lower socioeconomic (SES) status, underserved rural communities, and sexual and gender minority groups.
Funding Opportunity PAR-23-282 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities
Funding Opportunity PAR-24-049 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.
Notice NOT-OD-24-025 from the NIH Guide for Grants and Contracts